Not only for MSI-H! A combination of two approved drugs is in Phase III trial for MSS colorectal cancer
Background - The combination of regorafenib (Stivarga) and nivolumab (Opdivo) will be compared with regorafenib alone in a phase III trial of patients with microsatellite stable (MSS) colorectal (CRC), cancer,…